tirzepatide coming off FDA confirms shortage is still over, gives compounders a grace period Research finds that patients on

Per publicly available announcements, the FDA issued more than 50 warning letters to GLP-1 compounders and manufacturers in September 2025, followed by 30 additional warning letters to telehealth firms in early 2026, targeting false or misleading marketing claims about compounded GLP-1 products

This gatekeeping approach means patients with A1C levels between 5.7% and 6.4%the clinical definition of prediabetesfall outside covered indications, even though clinical evidence supports early intervention

If your lifestyle or labs suggest higher oxidative stress, a glutathione supplement can help

Diagnoses on Medicare Advantage chart reviews were not included in the creation of the condition flags

Mechanistically, the neuroprotective effect is mediated by the PI-3K activation (Hossain et al., 2002)